Philip W. Iversen
- Oncology top 2%
- Cancer-related Molecular Pathways 7
- Pancreatic and Hepatic Oncology Research 4
- PARP inhibition in cancer therapy 4
- Genetics top 5%
- Cancer Research top 5%
- Cancer Genomics and Diagnostics 4
- Molecular Biology top 5%
- DNA Repair Mechanisms 7
- PI3K/AKT/mTOR signaling in cancer 4
- Angiogenesis and VEGF in Cancer 4
-
- Computational Drug Discovery Methods 7
- Co-authors
- Jeremy R. GraffBrian J. EastwoodG. Sitta SittampalamBlake Lee NeubauerKaren L. CoxBruce W. KonicekMarı́a José LallenaFritz F. Parl
- Cited by
- OncologyGeneticsCancer Research
- Partner nations
- United StatesSpainUnited Kingdom
In The Last Decade
Philip W. Iversen
59 papers receiving 3.3k citations
Hit Papers
Peers
Comparison fields: 5 of 137
- Oncology 1.3k
- Genetics 318
- Cancer Research 405
- Molecular Biology 1.8k
- Pulmonary and Respiratory Medicine 693
Countries citing papers authored by Philip W. Iversen
This map shows the geographic impact of Philip W. Iversen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip W. Iversen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip W. Iversen more than expected).
Fields of papers citing papers by Philip W. Iversen
This network shows the impact of papers produced by Philip W. Iversen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip W. Iversen. The network helps show where Philip W. Iversen may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Philip W. Iversen, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2022 | 3 | |
| 2 | 2019 | 8 | |
| 3 | 2018 | 47 | |
| 4 | 2018 | 267 | |
| 5 | 2018 | 8 | |
| 6 | 2018 | 16 | |
| 7 | 2017 | 39 | |
| 8 | 2017 | 58 | |
| 9 | 2016 | 62 | |
| 10 | 2016 | 9 | |
| 11 | Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabinebreakdown → | 2014 | 446 |
| 12 | 2014 | 47 | |
| 13 | 2011 | 102 | |
| 14 | 2006 | 100 | |
| 15 | 2004 | 11 | |
| 16 | 2004 | 97 | |
| 17 | 2004 | 17 | |
| 18 | 2000 | 5 | |
| 19 | 1997 | 43 | |
| 20 | 1997 | 33 |
About Philip W. Iversen
Philip W. Iversen is a scholar working on Oncology, Cancer Research and Statistics and Probability, having authored 59 papers that have together received 3.4k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (7 papers), Cancer-related Molecular Pathways (7 papers), Computational Drug Discovery Methods (7 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Pancreatic and Hepatic Oncology Research (4 papers), Cancer Genomics and Diagnostics (4 papers), Angiogenesis and VEGF in Cancer (4 papers) and PARP inhibition in cancer therapy (4 papers). The work is most often cited by research in Oncology (1.3k citations), Genetics (318 citations) and Cancer Research (405 citations). Philip W. Iversen has collaborated with scholars based in United States, Spain and United Kingdom. Frequent co-authors include Jeremy R. Graff, Brian J. Eastwood, G. Sitta Sittampalam, Blake Lee Neubauer, Karen L. Cox, Bruce W. Konicek, Marı́a José Lallena, Fritz F. Parl, James G. Herman and Edward Gabrielson. Their work appears in journals such as Journal of Biological Chemistry, Blood and Cancer Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.